Company profile: Renibus Therapeutics
1.1 - Company Overview
Company description
- Provider of therapeutics to prevent and treat kidney disease, with RBT-1 (single-dose IV before elective cardiac surgery to reduce post-operative complications; Phase 3), Veverimer (oral hydrochloric acid binder for orphan diseases), RBT-3 (iron nanoparticle to restore iron and improve blood product use in cardiac surgery and ER), RBT-9 (anti-inflammatory/antioxidant for COVID-19), and RBT-2 (oral antioxidant/antifibrotic to delay CKD).
Products and services
- RBT-1: Phase 3-stage intravenous pharmacologic product administered 24–48 hours before elective cardiac surgery to reduce post-operative complications and improve outcomes through a single-dose regimen
- Veverimer: Non-absorbed oral hydrochloric acid binder (acquired from Tricida) targeting orphan diseases with unmet medical needs, binds hydrochloric acid without systemic absorption for therapeutic effect
- RBT-3: Low molecular weight iron nanoparticle engineered to rapidly restore iron levels and improve blood product utilization in cardiac surgery and emergency room patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Renibus Therapeutics
A1M Pharma
HQ: Sweden
Website
- Description: Provider of alpha 1 microglobulin, a body protein that is of major importance for the body's defense against oxidative stress.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full A1M Pharma company profile →
Purespring Therapeutics
HQ: United Kingdom
Website
- Description: Provider of AAV gene therapy programs for kidney diseases, targeting podocytes to address monogenic and more common forms, and the FunSel in‑vivo AAV-based screening platform that utilizes libraries of biological factors to identify new kidney gene therapy candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Purespring Therapeutics company profile →
Cadrenal Therapeutics
HQ: United States
Website
- Description: Provider of Tecarfarin, a late-stage novel oral anticoagulant targeting a different metabolic pathway than warfarin for patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). Under development for anticoagulation needs of left ventricular assist device (LVAD) patients and those with Antiphospholipid Syndrome (APS), aiming for safer alternatives to warfarin.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cadrenal Therapeutics company profile →
Allena Pharmaceuticals
HQ: United States
Website
- Description: Provider of non-systemic protein therapeutics to treat metabolic and orphan diseases, engaged in development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allena Pharmaceuticals company profile →
MediBeacon
HQ: United States
Website
- Description: Provider of optical diagnostic solutions for non-invasive organ function measurement, including the Transdermal GFR Measurement System (TGFR) that assesses kidney function via a fluorescent tracer (Lumitrace) detected through the skin, plus TGFR Sensors and Monitors for real-time data. Also offers novel fluorescent tracer agents and highly engineered transdermal sensors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MediBeacon company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Renibus Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Renibus Therapeutics
2.2 - Growth funds investing in similar companies to Renibus Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Renibus Therapeutics
4.2 - Public trading comparable groups for Renibus Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →